Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammatory Cytokine Response Clear all
Terminated Phase 3 Interventional Results available

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

NCT04377620
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
35
States / cities
Scottsdale, Arizona • San Diego, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 2, 2026, 5:26 PM EDT
Completed No phase listed Observational Results available

Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease

NCT02194439
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 2, 2026, 5:26 PM EDT
Completed No phase listed Observational

Inflammatory Cytokine Variations in Traumatic Injury Responses

NCT00593892
View directory record Official record
Conditions
Traumatic Complication of Injury
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Sep 2, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Astaxanthin, Exercise Inflammation, Skin Health

NCT05409092
View directory record Official record
Conditions
Inflammatory Response, Metabolic Disturbance, Immune Suppression
Interventions
Astaxanthin, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 57 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 2, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease

NCT00250198
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 2, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

NCT04071366
View directory record Official record
Conditions
Cytokine Release Syndrome
Interventions
Itacitinib, Immune effector cell therapy, Placebo, Yescarta
Drug · Biological
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 2, 2026, 5:26 PM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 2, 2026, 5:26 PM EDT
Active, not recruiting Phase 1 Interventional

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

NCT03016377
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
Interventions
iC9-CAR19 cells, Rimiducid, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
3 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2037
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 2, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Chronic Alcohol, Stress Inflammatory Response and Relapse Risk

NCT02193204
View directory record Official record
Conditions
Alcohol Dependence, Depressive Symptomatology
Interventions
Personal Stress Imagery, Neutral Imagery
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 2, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Auricular Vagus Nerve Stimulation on the Pro-inflammatory Cytokine Response in Healthy Adults

NCT01569789
View directory record Official record
Conditions
Cytokine Response to Vagus Nerve Stimulation
Interventions
Vagus Nerve Stimulator
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 2, 2026, 5:26 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Pre-emptive Anakinra for Cytokine Event Reduction

NCT06703216
View directory record Official record
Conditions
B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome, Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome
Interventions
Anakinra (Kineret®)
Drug
Lead sponsor
Kevin McNerney
Other
Eligibility
1 Year to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 2, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections

NCT00004996
View directory record Official record
Conditions
Healthy, Helminthiasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 2, 2026, 5:26 PM EDT
Completed Not applicable Interventional

UNITE Study (UMN-GE) for COVID-19

NCT04701489
View directory record Official record
Conditions
Covid19, Cytokine Storm, Inflammation
Interventions
Splenic ultrasound
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 2, 2026, 5:26 PM EDT
Terminated Not applicable Interventional

Study of the Effect of Regional Nerve Blocks on Pain and Inflammation After Video Assisted Thorascopic Lung Surgery

NCT00639795
View directory record Official record
Conditions
Pain
Interventions
Thoracic Paravertebral Nerve Block
Procedure
Lead sponsor
Memorial Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Johnstown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 2, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

NCT04540120
View directory record Official record
Conditions
Covid19, Cytokine Release Syndrome
Interventions
dapansutrile capsules, placebo capsules
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Coral Gables, Florida • Fort Lauderdale, Florida • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 2, 2026, 5:26 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients

NCT04252651
View directory record Official record
Conditions
Inflammatory Response, Multi Organ Failure, Nosocomial Infection, Deep Vein Thrombosis
Interventions
Blood Draw
Other
Lead sponsor
Joseph M. Still Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 2, 2026, 5:26 PM EDT
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 2, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Cytokine Removal by CRRT in Pediatric Sepsis

NCT00537693
View directory record Official record
Conditions
Sepsis
Interventions
Continuous Renal Replacement Therapy
Procedure
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
1 Year to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
Washington D.C., District of Columbia • St. Petersburg, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2010 · Synced Sep 2, 2026, 5:26 PM EDT
Terminated Not applicable Interventional

The Effect of Nighttime Dialysis on the Inflammation of Kidney Failure

NCT00234130
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
nocturnal vs conventional dialysis
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Sep 2, 2026, 5:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy

NCT05905328
View directory record Official record
Conditions
Cytokine Release Syndrome
Interventions
CTO1681 10 µg, CTO1681 20 μg, CTO1681 30 μg, CTO1681 10 µg Run-in / 20 µg Treatment, CTO1681 20 µg Run-in / 30 µg Treatment
Drug
Lead sponsor
CytoAgents, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Orange, California • Augusta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 5:26 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Pharmacology of Exenatide in Pediatric Sepsis

NCT01573806
View directory record Official record
Conditions
Septic Shock, Inflammation, Glucose Homeostasis, Organ Dysfunction, Health-related Quality of Life
Interventions
Exenatide, Exenatide vehicle
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 2, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Vaginal Probiotics and Pessaries and Their Impact on the Vaginal Microenvironment

NCT04118049
View directory record Official record
Conditions
Pelvic Organ Prolapse, Inflammatory Response, Dysbiosis
Interventions
BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) and RestoreTM gel., Standard Care
Other
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 2, 2026, 5:26 PM EDT
Active, not recruiting No phase listed Observational

Inflammatory Response Following Intraarticular Fracture

NCT01514643
View directory record Official record
Conditions
Intraarticular Fracture and Post-traumatic Osteoarthritis
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 2, 2026, 5:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cytokine Response to Abdominal Wall Reconstruction

NCT07422584
View directory record Official record
Conditions
Incisional Ventral Hernia
Interventions
Not applicable- observational study
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 2, 2026, 5:26 PM EDT